Purpose of review: This article presents an update on the clinical pharmacology, mechanisms of action, and safety of second generation antihistamines (SGAHs).
Recent findings: Recent research has shown the efficacy and good tolerance of SGAHs supporting its indication as first line medications for the treatment of allergic rhinoconjunctivitis and urticaria.
Summary: The information contained in this review is relevant for the correct utilization of SGAHs by practicing physicians who take care of these highly prevalent clinical disorders.